Surmodics (SRDX) Stock Price, News & Analysis

Company Overview

Surmodics, Inc. (NASDAQ: SRDX) is a medical technology company specializing in surface modification and drug-eluting coating technologies for medical devices and in vitro diagnostic applications. The company’s core expertise lies in polymer-based solutions that enhance device performance, including hydrophilic coatings to improve catheter lubricity and drug-delivery coatings for cardiovascular and peripheral vascular stents. Surmodics also offers proprietary diagnostic assay platforms and automation solutions for clinical laboratories.

Surmodics’ product portfolio is organized around two main segments: medical device and in vitro diagnostics. In the medical device segment, the company provides therapeutic delivery coatings, surface modifiers, and adhesive technologies for customers developing implants, guide wires, and catheters. On the diagnostics side, Surmodics supplies reagents, assay calibrators, and control materials, as well as instrumentation used in immunoassay and molecular diagnostic workflows.

Founded in Eden Prairie, Minnesota, in 1986, Surmodics has expanded its operations to serve a global client base across North America, Europe, and Asia. The company’s research and development efforts focus on advancing biocompatible polymers and next-generation delivery systems, while its manufacturing facilities adhere to international quality standards. Surmodics collaborates with a diverse set of medical device OEMs, contract manufacturers, and diagnostic companies to bring customized surface and assay solutions to market.

Surmodics is led by President and Chief Executive Officer Richard Carlin, who has overseen strategic partnerships and product launches since taking the helm in 2016. The company maintains a governance structure aimed at innovation and regulatory compliance, with a board comprised of directors experienced in medical technology, life sciences, and global business operations. Through ongoing investment in R&D and customer-driven development, Surmodics seeks to address clinical challenges and improve patient outcomes worldwide.

Key Stats

• Today's Range: $41.85 to $43.00
• 50-Day Range: $26.42 to $42.98
• 52-Week Range: $25.87 to $43.00
• Volume: 5.34 million shs
• Average Volume: 269,318 shs
• Market Capitalization: $614.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Surmodics Stock Analysis - MarketRank™

Surmodics scored higher than 8% of companies evaluated by MarketBeat, and ranked 838th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Surmodics has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.

Amount of Analyst Coverage

Surmodics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 300.00%

Earnings Growth

Earnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surmodics is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surmodics is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Surmodics has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SRDX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surmodics does not currently pay a dividend.

Dividend Growth

Surmodics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Surmodics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surmodics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.90% of the stock of Surmodics is held by insiders.

Percentage Held by Institutions

96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/08/2025
• Today: 5/25/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:SRDX
• CIK: 924717
• Web: www.surmodics.com
• Phone: (952) 500-7000
• Fax: 952-500-7001
• Employees: 450
• Year Founded: 1979

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 214.90
• P/E Growth: N/A
• Net Income: -$11.54 million
• Net Margins: -14.59%
• Pretax Margin: -12.16%
• Return on Equity: -2.99%
• Return on Assets: -1.99%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 3.91
• Quick Ratio: 3.10

Sales & Book Value

• Annual Sales: $120.80 million
• Price / Sales: 5.09
• Cash Flow: $0.49 per share
• Price / Cash Flow: 87.04
• Book Value: $8.33 per share
• Price / Book: 5.16

Miscellaneous

• Outstanding Shares: 14,298,000
• Free Float: 13,025,000
• Market Cap: $614.53 million
• Optionable: Optionable
• Beta: 1.30